Mud fam,
As the psychedelic renaissance takes root, researchers are testing derivatives of psilocybin that … wait for it … don’t cause a psychedelic trip.
This “decaf” version of psilocybin targets the same serotonin receptors as traditional mushrooms, but doesn't cause hallucinations. Proponents of this derivative say that it may increase accessibility, but others (like yours truly) can’t help but wonder if we aren’t bastardizing the sacred medicine by removing the hallucinogenic properties.
This week on Trends w/ Benefits, Damon Orion explores these questions and more in “Is This Trip Really Necessary?” Us Westerners love to remove discomfort, but when we apply this philosophy to psychedelics, it may come with a cost. As Joseph Campbell wrote, “The cave you fear to enter holds the treasure you seek.”
Have a great weekend,
Shane
Founder & CEO
|